Rosetta Genomics Ltd. (NASDAQ: ROSG), a developer and provider of microRNA-based molecular diagnostics and therapeutics, has announced that the company has entered into an agreement with Moffitt Cancer Center to advance the development and commercialization of Rosetta's thyroid neoplasia assay.
Under the agreement, Rosetta will work with Dr Marino Leon, associate member of the Department of Anatomic Pathology at Moffitt.
Rosetta Genomics president and CEO Kenneth Berlin said that this agreement is a significant step forward in the development of the company’s key pipeline project, an assay for the differential diagnosis of indeterminate thyroid FNAs.
"We believe that working with experts like Dr. Leon and others at Moffitt will significantly enhance and accelerate the development of our thyroid neoplasia assay, Berlin added.
"Results from our initial studies demonstrated that microRNA expression levels can differentiate malignant nodules from benign nodules, and also demonstrated our ability to extract and profile microRNAs from thyroid FNAs in various sample types and in a way consistent with common clinical practices.
This agreement with Moffitt will help us further advance the development of this important assay, and should allow us to achieve our goal of launching this important assay prior to the end of 2015."